about
Structural Basis for the Function of Complement Component C4 within the Classical and Lectin Pathways of ComplementAnti-cholesterol antibodies (ACHA) in patients with different atherosclerotic vascular diseases and healthy individuals. Characterization of human ACHAComplement protease MASP-1 activates human endothelial cells: PAR4 activation is a link between complement and endothelial functionTraitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine developmentHuman serum fetuin A/alpha2HS-glycoprotein level is associated with long-term survival in patients with alcoholic liver cirrhosis, comparison with the Child-Pugh and MELD scoresDiagnosis and classification of hemolytic uremic syndrome: the Hungarian experience.Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.Elevated plasma neutrophil elastase concentration is associated with disease activity in patients with thrombotic thrombocytopenic purpura.Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report.First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosisThe major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease.Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome.Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome.The role of human leukocyte antigen DRB1-DQB1 haplotypes in the susceptibility to acquired idiopathic thrombotic thrombocytopenic purpura.Circulating heat shock protein 70 (HSPA1A) in normal and pathological pregnancies.Common genetic variants of the human steroid 21-hydroxylase gene (CYP21A2) are related to differences in circulating hormone levels.High levels of acute phase proteins and soluble 70 kDa heat shock proteins are independent and additive risk factors for mortality in colorectal cancerInflammation and oxidative stress caused by nitric oxide synthase uncoupling might lead to left ventricular diastolic and systolic dysfunction in patients with hypertension.Both positive and negative selection pressures contribute to the polymorphism pattern of the duplicated human CYP21A2 geneSerum leptin levels in relation to circulating cytokines, chemokines, adhesion molecules and angiogenic factors in normal pregnancy and preeclampsiaIncreased circulating heat shock protein 70 (HSPA1A) levels in gestational diabetes mellitus: a pilot studyImmunological aspects of heat-shock proteins-the optimum stress of life.Antibodies against heat shock proteins and cholesterol in HIV infection.Comprehensive study into the activation of the plasma enzyme systems during attacks of hereditary angioedema due to C1-inhibitor deficiency.Measurement of the Red Blood Cell Distribution Width Improves the Risk Prediction in Cardiac Resynchronization Therapy.Chaperones as part of immune networks.Persistently elevated extracellular HSP70 (HSPA1A) level as an independent prognostic marker in post-cardiac-arrest patientsThe ratio of the neutrophil leucocytes to the lymphocytes predicts the outcome after cardiac resynchronization therapy.Interaction of serum 70-kDa heat shock protein levels and HspA1B (+1267) gene polymorphism with disease severity in patients with chronic heart failureElevated extracellular HSP70 (HSPA1A) level as an independent prognostic marker of mortality in patients with heart failure.Increased serum heat-shock protein 70 levels reflect systemic inflammation, oxidative stress and hepatocellular injury in preeclampsiaCirculating anti-heat-shock-protein antibodies in normal pregnancy and preeclampsia.Heat shock protein 70 is a potent activator of the human complement system.Role of complement in the pathomechanism of atherosclerotic vascular diseases.Evidence-based hydro- and balneotherapy in Hungary--a systematic review and meta-analysis.Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome.Inflammatory- and immune responses in relation to bacterial replication in mice following re-infections with Chlamydophila pneumoniae.Association of Chlamydia pneumoniae with coronary artery disease and its progression is dependent on the modifying effect of mannose-binding lectin.Independent and joint effects of antibodies to human heat-shock protein 60 and Chlamydia pneumoniae infection in the development of coronary atherosclerosis.[The Danubian Biobank Initiative: synchronizing the biobanking activities of the Danube universities].
P50
Q27700252-AE8F1061-F078-445C-96C2-2196FDB98132Q28190108-454B184F-95B7-4449-88B6-AC612F799308Q28254333-9B045BCD-D9A0-4A45-869B-028A9A425D2EQ28266913-D85D0B16-3990-4524-880A-4F1AB97CDE6EQ33280499-85E542A1-D244-4D4D-830D-F01373F95C36Q33395539-E64908C4-4659-4C15-AB8E-30C1FDECC765Q33413104-632FC090-202F-457B-9853-DA91B8A3F590Q33413402-6AFA0681-1B64-4557-938F-4BE92F78D46AQ33419171-7AC59E47-DFF7-4FC3-B498-95E4EF708CD4Q33419275-67564B97-3AF8-4ED8-B5C8-DE728680F1FEQ33420213-CB88CC86-E71B-4108-AA07-20F27C25C3BEQ33428684-6918CD97-9C61-4E1B-AF6A-03D1F0F94731Q33429638-25BFD83E-2781-4BAE-8618-7EEBE1CCF999Q33436965-7B4103A7-0ECE-4CC8-9127-C9E8819D46F6Q33838958-F7ABCCB3-9EFB-466E-BB91-B246C6F06B23Q34166429-40E47594-5B6C-4B6D-BB38-7A2B02C9E837Q34505866-49200FC2-58F2-47D7-8107-34B98A93056AQ35019654-00811BAE-7188-4371-99C7-4AAA94AE280CQ35060828-D0EF8674-F399-482E-B6F5-EB9023EDF9A7Q35252411-36A92E49-C972-4453-844B-89235F9A9702Q35725127-5311FB9D-7309-4B1A-948D-ABD0D7D508EEQ35771938-0E529706-1F42-4A34-8F9C-01DFA8F37790Q35920384-07E1D5E8-E671-41D6-BACD-4EDFA0305798Q36144212-9BF241C2-0D00-421A-9112-E3A55B5799EAQ36556242-8AFE244D-C162-4567-A501-FEB998729FCAQ36700340-A713BD90-3F7A-410C-A771-8EE4359C4393Q36927338-A1308384-CE74-4C49-BEE7-9E0585F3FDD8Q36935337-8F0C146C-67BE-4534-9665-CAF30AD4D06DQ37170872-332BFB97-6E94-4ADE-8C04-DDEADD67B162Q37213585-4A2A1618-CC9F-4DEA-BF31-A160838FA0FCQ37308072-C9523711-99FA-4075-8154-C1BE03D6158EQ37308870-682DB365-80B2-4459-A953-0A0B58B57FDEQ37489832-05A37867-BEDF-40F2-80C7-EE3F21EAB09DQ37510199-A68AA02F-EB98-44C4-A78E-1598E9DA2454Q37638880-802141F0-8FB2-4DEE-8DFD-90126E13400BQ37727489-5B68E1EA-D8C6-4995-ADFA-F19C2C4EFE93Q37857387-4DDC3006-331B-4E90-86DA-D17BEBCBD10AQ37871349-47396E24-119D-404D-B089-21A40FE6D64DQ37874609-0C73A6A3-411A-4651-8695-BED0108BE2D1Q38445985-ABA29E8D-32F7-4415-8185-33364112AE81
P50
description
Hongaars onderzoeker
@nl
forsker
@nb
magyar kutató
@hu
researcher
@en
հետազոտող
@hy
name
Prohászka Zoltán
@hu
Z. Prohaszka
@ast
Z. Prohaszka
@nl
Z. Prohaszka
@sl
Zoltan Prohaszka
@en
Zoltan Prohaszka
@es
Zoltan Prohaszka
@nb
Zoltan Prohaszka
@sq
type
label
Prohászka Zoltán
@hu
Z. Prohaszka
@ast
Z. Prohaszka
@nl
Z. Prohaszka
@sl
Zoltan Prohaszka
@en
Zoltan Prohaszka
@es
Zoltan Prohaszka
@nb
Zoltan Prohaszka
@sq
altLabel
Z. Prohaszka
@en
prefLabel
Prohászka Zoltán
@hu
Z. Prohaszka
@ast
Z. Prohaszka
@nl
Z. Prohaszka
@sl
Zoltan Prohaszka
@en
Zoltan Prohaszka
@es
Zoltan Prohaszka
@nb
Zoltan Prohaszka
@sq
P106
P1153
7003447622
P21
P27
P31
P496
0000-0003-1761-7982